Ones To Watch News
Refine Search
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Biotechnology
California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, has announced the closing of a $120 million Series C financing round. 12 December 2024
Biotechnology
Utah, USA-based privately-held biotech Halia Therapeutics has announced promising top-line data resulting in the advancement to the second stage of its Phase II clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk myelodysplastic syndromes (LR-MDS). 12 December 2024
Pharmaceutical
Neuraxpharm Group, a privately-held specialty pharma focused on central nervous system (CNS) disorders, and Greek drugmaker Pharmathen, a developer and supplier of long-acting injectable (LAI) therapies, have announced a strategic alliance. 12 December 2024
Biotechnology
US clinical-stage biotech Q32 Bio saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed update on its research pipeline, that analysts called “messy.” 12 December 2024
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it announced results from a multicenter Phase III clinical trial evaluating its CAN-2409 viral immunotherapy in localized prostate cancer patients. 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Pharmaceutical
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. 9 December 2024
Biotechnology
Dutch biotech Citryll, which is focused on treating immune-mediated inflammatory diseases by targeting neutrophil extracellular traps (NETs), today announced the successful closing of an oversubscribed 85 million euros ($89.8 million) Series B fundraise. 9 December 2024
Biotechnology
Leading early-stage biotech investor Atlas Ventures has closed its fourteenth fund with $450 million in an oversubscribed raise. 6 December 2024
Biotechnology
Ophthalmic gene therapy company Beacon Therapeutics Holdings has announced the presentation of three-month interim safety and efficacy results of AGTC-501 (laruparetigene zovaparvovec; laru-zova) in the Phase II DAWN trial in patients with X-linked retinitis pigmentosa (XLRP at the FLORetina-ICOOR Meeting 2024 in Florence, Italy. 6 December 2024
Biotechnology
Menlo Park-based Nuvig Therapeutics has raised $161 million in a series B financing round co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. 6 December 2024
Biotechnology
Privately-held Muna Therapeutics, a Danish biotech focused on neurodegenerative diseases, has announced a research alliance with UK pharma major GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. 5 December 2024
Biotechnology
Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ublituximab (150mg concentrate for solution for infusion) in the treatment of relapsing-remitting multiple sclerosis (RRMS). 5 December 2024
Biotechnology
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from Dutch firm Merus NV, whose shares edged up 1.8% to $46.32 on the news. 5 December 2024
Biotechnology
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Biotechnology
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Biotechnology
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Biotechnology
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze